Vitamin C may fight cancer — but not the way scientists once thought

Modern research is re-evaluating the role of high-dose vitamin C in cancer treatment, noting that intravenous administration may have different biological effects than oral supplements. This challenges earlier clinical trials that dismissed the treatment based on oral-only testing.
Why it matters
It highlights the importance of delivery methods in pharmacology and the potential for revisiting discarded medical hypotheses.
Linus Pauling was one of the most brilliant scientists of the 20th century. He won two Nobel prizes and transformed our understanding of chemical bonds and the structure of proteins. Late in his career, though, he became famous for something very different: a passionate belief that very high doses of vitamin C could help people with cancer. Many doctors scoffed. When Pauling himself later died of cancer aged 93, he was held up as a classic case of the "halo effect": being a genius in one field doesn't guarantee wisdom in another.
Half a century on, the story looks more complicated. Pauling was wrong in important ways, but he was not entirely wrong. Modern research is giving vitamin C a second look in cancer, and it turns out that under certain conditions it can behave less like a gentle vitamin and more like a drug .
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in